(65 days)
Not Found
Not Found
No
The description details a standard ELISA assay with optical density measurement and ratio calculation, with no mention of AI or ML in the device description, performance studies, or key metrics.
No.
This device is an in vitro diagnostic (IVD) test kit used to detect specific antibodies to aid in the diagnosis of systemic vasculitis. It does not directly treat or prevent a disease, which is the function of a therapeutic device.
Yes
The device is an ELISA test kit intended for the qualitative detection of specific antibodies in human sera. Its results "are to be used as an aid to the diagnosis of systemic vasculitis," which directly relates to diagnosing a medical condition.
No
The device description clearly outlines a physical test kit involving microtiter strips, reagents, incubations, washing steps, and measurement of optical density. This is a laboratory-based assay kit, not a software-only device.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states that the kit is for the "qualitative detection of antibodies... in human sera." This indicates that the device is used to examine specimens derived from the human body.
- Purpose: The results are used "as an aid to the diagnosis of systemic vasculitis." This clearly indicates a medical purpose related to diagnosing a disease.
- Method: The device uses an "enzyme-linked immunosorbent assay (ELISA)," which is a common in vitro diagnostic technique.
- Specimen: The assay is performed on "human sera," which is a biological specimen taken from a human.
All of these points align with the definition of an In Vitro Diagnostic device, which is a medical device intended for use in vitro for the examination of specimens derived from the human body solely or principally for the purpose of providing information concerning a physiological state, state of health, or disease or congenital abnormality.
N/A
Intended Use / Indications for Use
The Wielisa ANCA Screening Test Kit is an enzyme-linked immunosorbent assay (ELISA) for the qualitative detection of antibodies to Proteinase-3 (PR-3) and Myeloperoxidase (MPO) in human sera. The assay is used to detect antibodies in a single serum specimen. The results of the assay are to be used as an aid to the diagnosis of systemic vasculitis, especially Wegener's granulomatosis (WG) and microcopic polyangiitis (MP). The assay is intended for use in patients with signs and symptoms consistent with systemic vasculitis. It is not intended for screening a healthy population. A positive result should always be confirmed by a semi-quantitative assay.
Product codes
MOB
Device Description
The Wielisa ANCA Screening Test Kit is an enzyme-linked II. immunosorbent assay (ELISA) for the qualitative detection of antibodies to Proteinase-3 (PR-3) and Myeloperoxidase (MPO) in human sera. The assay is used to detect antibodies in a single serum specimen. The results of the assay are to be used as an aid to the diagnosis of systemic vasculitis, especially Wegener's granulomatosis (WG) and microcopic polyangiitis (MP). The assay is intended for use in patients with signs and symptoms consistent with systemic vasculitis. It is not intended for screening a healthy population. A positive result should always be confirmed by a semi-quantitative assay.
The wells of the microtiter strips are coated with purified (Human Neutrophil source) proteinase 3, and MPO (Human Neutrophil source) antigen. During the first incubation, specific antibodies in diluted serum, will bind to the antigen coating.
The wells are then washed to remove unbound antibodies and other components. A conjugate of alkaline phosphatase-labeled (Goat) antibodies to human IgG binds to the antibodies in the wells in this second incubation.
After a further washing step, detection of specific antibodies is obtained by incubation with substrate solution. The amount of bound antibodies correlates to the color intensity and is measured in terms of absorbance (optical density (OD)). The absorbance is then calculated and the results are given as a ratio to the negative control.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Clinical sensitivity and specificity study:
A total of 288 frozen retrospective sera with clinical characterisation were assayed.
Clinical sensitivity (Equivocal samples not included in the calculations):
PR3-ANCA: WG = 39/42 = 92.9 % (95% CI = 84.9-100%); MP = 21/41 = 51.2 % (95% CI = 35.6-66.8%)
MPO-ANCA: WG = 4/41 = 9.8 % (95% CI = 4.9-19.0%); MP = 20/43 = 46.5 % (95% CI = 31.3-61.7%)
Clinical specificity (Equivocal samples not included in the calculations):
PR3-ANCA: SLE = 31/31 = 100 % (95% CI = 90.4-100%); RA = 41/41 = 100 % (95% CI = 92.7-100%); NS = 131/131 = 100 % (95% CI = 97.6-100%)
MPO-ANCA: SLE = 24/29 = 82.8 % (95% CI = 68.7-96.8%); RA = 40/40 = 100 % (95% CI = 92.6-100%); NS = 127/127 = 100 % (95% CI = 97.6-100%)
Relative sensitivity and specificity study:
A total of 216 frozen retrospective sera were assayed comparing the Wielisa ANCA screen kit to a semi-quantitative ELISA. Sera falling in the equivocal range were not included in the calculations.
Relative sensitivity PR3-ANCA = 59/60 = 98.3 % (95% CI = 95.0-100%)
Relative sensitivity MPO-ANCA = 23/24 = 95.8 % (95% CI = 87.7-100%)
Relative specificity PR3-ANCA = 152/152 = 100 % (95% CI = 98.0-100%)
Relative specificity MPO-ANCA = 182/182 = 100 % (95% CI = 98.4-100%)
Batch to batch variation study:
Tested three different samples across 4 different batches.
Sample 2 (PR3): Mean OD ratio = 34.5, SD = 1.0, CV = 3%
Sample 5 (PR3): Mean OD ratio = 19.8, SD = 2.2, CV = 11%
Sample 8 (PR3): Mean OD ratio = 33.8, SD = 1.5, CV = 4%
Sample 3 (MPO): Mean OD ratio = 16.3, SD = 3.9, CV = 24%
Sample 6 (MPO): Mean OD ratio = 27.8, SD = 2.1, CV = 7%
Sample 9 (MPO): Mean OD ratio = 23, SD = 2.9, CV = 13%
Inter-assay precision study:
Tested one sample across six different runs.
PK (PR3): OD ratio = 27.3, SD = 2.9, CV = 11%
K5 (PR3): OD ratio = 12.1, SD = 1.2, CV = 10%
PK (MPO): Mean OD ratio = 17.3, SD = 3.8, CV = 21%
K6 (MPO): Mean OD ratio = 16.5, SD = 0.84, CV = 5%
Intra-assay precision study:
Tested one sample in 22 wells.
PK (PR3): Mean OD = 1.3, SD = 0.07, CV = 6%
K5 (PR3): Mean OD = 1.3, SD = 0.06, CV = 5%
PK (MPO): Mean OD = 1.9, SD = 0.06, CV = 3%
K6 (MPO): Mean OD = 1.46, SD = 0.07, CV = 5%
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Clinical sensitivity and specificity are provided, as well as relative sensitivity and specificity.
Clinical sensitivity:
PR3-ANCA: WG = 92.9 %, MP = 51.2 %
MPO-ANCA: WG = 9.8 %, MP = 46.5 %
Clinical specificity:
PR3-ANCA: SLE = 100 %, RA = 100 %, NS = 100 %
MPO-ANCA: SLE = 82.8 %, RA = 100 %, NS = 100 %
Relative sensitivity:
PR3-ANCA = 98.3 %
MPO-ANCA = 95.8 %
Relative specificity:
PR3-ANCA = 100 %
MPO-ANCA = 100 %
Predicate Device(s)
Not Found
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 866.5660 Multiple autoantibodies immunological test system.
(a)
Identification. A multiple autoantibodies immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the autoantibodies (antibodies produced against the body's own tissues) in serum and other body fluids. Measurement of multiple autoantibodies aids in the diagnosis of autoimmune disorders (disease produced when the body's own tissues are injured by autoantibodies).(b)
Classification. Class II (performance standards).
0
JUL 22 1998
Summary of Safety and Effectiveness Information ANCA Screening ELISA Test Kit
I. Wieslab AB Ideon Research Park S-223 70 Lund Sweden Contact person: Dr. Jorgen Wieslander Telephone: 46-46-182840 Date of preparation: May 1, 1998
Description of Device: The Wielisa ANCA Screening Test Kit is an enzyme-linked II. immunosorbent assay (ELISA) for the qualitative detection of antibodies to Proteinase-3 (PR-3) and Myeloperoxidase (MPO) in human sera. The assay is used to detect antibodies in a single serum specimen. The results of the assay are to be used as an aid to the diagnosis of systemic vasculitis, especially Wegener's granulomatosis (WG) and microcopic polyangiitis (MP). The assay is intended for use in patients with signs and symptoms consistent with systemic vasculitis. It is not intended for screening a healthy population. A positive result should always be confirmed by a semi-quantitative assay.
The wells of the microtiter strips are coated with purified (Human Neutrophil source) proteinase 3, and MPO (Human Neutrophil source) antigen. During the first incubation, specific antibodies in diluted serum, will bind to the antigen coating.
The wells are then washed to remove unbound antibodies and other components. A conjugate of alkaline phosphatase-labeled (Goat) antibodies to human IgG binds to the antibodies in the wells in this second incubation.
After a further washing step, detection of specific antibodies is obtained by incubation with substrate solution. The amount of bound antibodies correlates to the color intensity and is measured in terms of absorbance (optical density (OD)). The absorbance is then calculated and the results are given as a ratio to the negative control.
III. Predicate Device
The ANCA Screening test is substantially equivalent to the Wielisa PR-3 ANCA ELISA Kit and the Wielisa MPO ANCA ELISA Kit. Equivalence is demonstrated by the following comparative results:
1
| Control and
Disease groups | Total | Negative 4
PR3 MPO |
| ------------------------------- | ------- | ------------------------ | -------------------------- | ------------------------ |
|---|
| Table 1. Clinical sensitivity and specificity. A total of 288 frozen retrospective sera with clinical | |
|---|---|
| characterisation were assayed. The following table summarises the results |
| Control and
| Disease groups | Total | Negative +3 | Equivocal +? | Positive +? | |||
|---|---|---|---|---|---|---|---|
| PR3 | MPO | PR3 | MPO | PR3 | MPO | ||
| Blood donors: (NS) | 131 | 131 | 127 | 0 | 4 | 0 | 0 |
| WG: | 42 | 3 | 37 | 0 | 1 | 39 | 4 |
| MP: | 43 | 20 | 23 | 2 | 0 | 21 | 20 |
| SLE: | 31 | 31 | 24 | 0 | 2 | 0 | *5 |
| RA: | 41 | 41 | 40 | 0 | 1 | 0 | 0 |
WG = Wegener's granulomatosis, MP = microscopic polyangiitis RA = rheumatoid arthritis
SLE = systemic lupus erythematosus GBM = glomerular basement membrane
*All samples were positive in the semi-quantitative MPO-ELISA.
Clinical sensitivity (Equivocal samples not included in the calculations)
| PR3-ANCA: | WG = 39/42 = 92.9 % | 95% CI = 84.9-100% |
|---|---|---|
| MP = 21/41 = 51.2 % | 95% CI = 35.6-66.8% | |
| MPO-ANCA: | WG = 4/41 = 9.8 % | 95% CI = 4.9-19.0% |
| MP = 20/43 = 46.5 % | 95% CI = 31.3-61.7% |
Clinical specificity (Equivocal samples not included in the calculations)
| PR3-ANCA: SLE = 31/31 = 100 % | 95% CI = 90.4-100% |
|---|---|
| RA = 41/41 = 100 % | 95% CI = 92.7-100% |
| NS = 131/131 = 100 % | 95% CI = 97.6-100% |
| MPO-ANCA: SLE = 24/29 = 82.8 % | 95% CI = 68.7-96.8% |
| RA = 40/40 = 100 % | 95% CI = 92.6-100% |
| NS = 127/127 = 100 % | 95% CI = 97.6-100% |
2
Table 2. Relative sensitivity and specificity of the Wielisa ANCA screen kit compared to an semi-quantitative ELISA. A total of 216 frozen retrospective sera were assayed. The following table summarises the results.
| Wielisa ANCA screen | |||||||
|---|---|---|---|---|---|---|---|
| Semi-quantitative ELISA | Negative 4 | ||||||
| PR3 | MPO | PR3 | MPO | ||||
| MPO-ANCA | Positive | 0 | 1 | 0 | 0 | 0 | 23 |
| PR3-ANCA | Positive | 1 | 0 | 0 | 0 | 59 | 0 |
| Negative | 152 | 182 | 2 | 4 | 0 | 0 | |
| Equivocal | 1 | 4 | 0 | 1 | 1 | 1 | |
| Total | 154 | 187 | 2 | 5 | 60 | 24 |
Sera falling in the equivocal range were are not including in the calculations:
| Relative sensitivity PR3-ANCA = 59/60 = 98.3 % | 95% CI = 95.0-100% |
|---|---|
| Relative sensitivity MPO-ANCA = 23/24 = 95.8 % | 95% CI = 87.7-100% |
| Relative specificity PR3-ANCA = 152/152 = 100 % | 95% CI = 98.0-100% |
| Relative specificity MPO-ANCA = 182/182 = 100 % | 95% CI = 98.4-100% |
.
3
| Sample
PR3 | Mean
OD ratio | SD | CV % | Sample
MPO | Mean
OD ratio | SD | CV % |
|---------------|------------------|-----|------|---------------|------------------|-----|------|
| 2 | 34.5 | 1.0 | 3 | 3 | 16.3 | 3.9 | 24 |
| 5 | 19.8 | 2.2 | 11 | 6 | 27.8 | 2.1 | 7 |
| 8 | 33.8 | 1.5 | 4 | 9 | 23 | 2.9 | 13 |
Table 3. Batch to batch variation was determined by testing three different samples. Results were obtained for 4 different batches.
Table 4. Inter-assay precision was determined by testing one sample. Results were obtained for six different runs.
| Sample | OD
ratio | SD | CV % | Sample
MPO | Mean
OD ratio | SD | CV % |
|--------|-------------|-----|------|---------------|------------------|------|------|
| PK | 27.3 | 2.9 | 11 | PK | 17.3 | 3.8 | 21 |
| K5 | 12.1 | 1.2 | 10 | K6 | 16.5 | 0.84 | 5 |
Table 5. Intra-assay precision was determined by testing one sample in 22 wells.
| Sample | Mean
OD | SD | CV % | Sample | Mean
OD | SD | CV % |
|--------|------------|------|------|--------|------------|------|------|
| PK | 1.3 | 0.07 | 6 | PK | 1.9 | 0.06 | 3 |
| K5 | 1.3 | 0.06 | 5 | K6 | 1.46 | 0.07 | 5 |
4
Image /page/4/Picture/2 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with three lines representing its body and wings. The eagle is positioned to the right of a circular border containing the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA". The text is arranged around the circumference of the circle.
JUL 2 2 1998
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Weislab AB c/o William L. Boteler, Jr. IMMUNO PROBE, INC. 1306 Bailes Lane, Suite F Frederick, MD 21701
K981748 Re: Trade Name: Wielisa ANCA Screening Test Kit Regulatory Class: II Product Code: MOB Dated: May 3, 1998 Received: May 18, 1998
Dear Mr. Boteler:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Druq, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual reqistration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such Existing major regulations affecting your device additional controls. can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General requlation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP requlation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal Laws or Regulations.
5
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770)488-7655.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll free number (800) 638-2041 or at (301) 443-6597 or at its
internet address "http://www.fda.gov/cdrh/dsmamain.html"
Sincerely yours,
Steven Sutman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
6
Page 1 of 1
K981748 510(k) Number: Not known
Device Name: Wielisa ANCA Screening Test Kit
Indications For Use: The Wielisa ANCA Screening Test Kit is an enzyme-linked immunosorbent assay (ELISA) for the qualitative detection of antibodies to Proteinase-3 (PR-3) and Myeloperoxidase (MPO) in human sera. The assay is used to detect antibodies in a single serum specimen. The results of the assay are to be used as an aid to the diagnosis of systemic vasculitis, especially Wegener's granulomatosis (WG) and : microcopic polyangiitis (MP). The assay is intended for use in patients with signs and symptoms consistent with systemic vasculitis. It is not intended for screening a healthy population. A positive result should always be confirmed by a semi-quantitative assay.
PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) _____________________________________________________________________________________________________________________________________________________________________________
Concurrence of CDRH, Office of Device Evaluation (ODE)
11 Prescription Use (Per 21 CFR 801.109)
OR
Over-The Counter Use (Optional Format 1-2-96)
Ji Ma
(Division Sign-Off)
Divotlinical Laboratory Devices K98,748
510(k) Number